1. In Vivo
  2. >>COVID-19

COVID-19 Vaccination Programs And Implications Of The Human Microbiome

 
• By Hannah Sally

It is vital to understand the role of the microbiome in immunity and vaccine response, and how the microbiome may impact the effectiveness of COVID-19 vaccine programs in the real world.

COVID-19 vaccination

The world is depending on the success of vaccine programs to end the ongoing COVID-19 pandemic. To curb the spread of the virus, it is essential for a population to reach herd immunity, where a significant proportion has developed immunity to infection. There are currently 11 vaccines authorized/approved for use in multiple countries worldwide. According to clinical trial data, these vaccines have demonstrated relatively high efficacy in preventing COVID-19 infection. However, this does not mean that the vaccines will be as effective in the real world. Vaccine response can vary at an individual level and can be influenced by a multitude of biological factors, including the function of the microbiome.

The microbiome plays a significant role in immunity, and may be an underlying factor explaining why elderly people and those...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff

 
• By Eleanor Malone

Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.

COVID To GLP-1: Catalent Plants Ride With Novo To Next Public Health Crisis

 
• By Bowman Cox

A complex transformation is underway as client proposes to acquire CDMO facilities that vaccinated the world against the COVID-19 pandemic for pivot to the obesity epidemic.

Outlook 2024: Biopharma Embraces New Markets And New Tech

 
• By Lucie Ellis-Taitt

New markets, a patent cliff, an M&A rebound and clinical trial catalysts. How will it all play out for the biopharma sector in 2024? 

After All The Layoffs, Is Biopharma’s Headcount Still Growing?

 
• By Andrew McConaghie

While biotech layoffs and big pharma restructuring dominate the news in 2023, the sector’s job market remains buoyant.

More from In Vivo

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier

 
• By Jo Shorthouse

Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By David Wild

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.